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Introduction: Effective biomarkers for early diagnosis of lung cancer 
are needed. A recent study demonstrated that urinary GM2-activator 
protein (GM2AP) level was increased in lung cancer patients. This 
study aims to validate the potential application of GM2AP as a bio-
marker for diagnosis of lung cancer.
Methods: Serum and urine samples were obtained from 189 par-
ticipants (133 patients for treatment naive lung cancer, 26 healthy 
volunteers for urine, and 30 healthy volunteers for serum). GM2AP 
level was detected by Western blotting and quantified using enzyme-
linked immunosorbent assay (ELISA). The GM2AP expression in 
tumors and nontumor parts of lung tissues from 143 nonsmall cell 
lung cancers was detected by immunohistochemical stains.
Results: There was an 8.11 ± 1.36 folds increase in urine and a 
5.41 ± 0.73 folds increase in serum level of GM2AP in lung cancer 
patients compared with healthy volunteers (p < 0.0001), achieving 
a 0.89 AUC value in urine and 0.90 AUC value in serum for the 
receiver-operating characteristic curves. Both serum and urine lev-
els of GM2AP correlated significantly with pathology stages (urine, 
p = 0.009; serum, p < 0.0001). Using immunohistochemical, positive 
expression of GM2AP was found at 83.9% of nonsmall cell lung 
cancers patients and none in normal tissue. The GM2AP expres-
sion was significantly correlated with pathology stage (p = 0.0001). 
Patients with higher GM2AP expression had shorter overall survival 
(p = 0.045) and disease-free survival (p = 0.049) than lower GM2AP 
expression. Moreover, the multivariate analysis suggested GM2AP 
as an independent predictors of disease-free survival and overall 
survival.
Conclusions: Our study demonstrates that GM2AP might serve as 
potential diagnostic and prognostic biomarkers in patients with lung 
cancer.
Key Words: Lung cancer, GM2-activator protein, Biomarker, 
Diagnosis.
(J Thorac Oncol. 2015;10: 102–109)
Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for 28% of all male cancer deaths 
and 26% of all female cancer deaths in the United States 
in 2013.1 Lung cancer can typically be grouped into two 
main categories such as small cell lung cancer (SCLC) and 
 nonsmall cell lung cancer (NSCLC), accounting for 15%, 
and 85% of lung cancers, respectively. NSCLC consists of 
three major histological subtypes such as adenocarcinoma, 
squamous cell carcinoma, and large cell carcinoma.2 Owing 
to lack of effective early detection tools and ineffective treat-
ments for the advanced stages, the 5-year survival rate of lung 
cancer is only 15%.3,4 Therefore, early detection is crucial and 
beneficial for lung cancer patients to receive appropriate and 
potentially curative treatments.
Two recent studies employed two-dimensional gel 
electrophoresis (2-DE) technique to identify urinary protein 
markers obtained from patients with lung cancer and healthy 
volunteers.5,6 The expression of GM2-activator protein 
(GM2AP) level in lung cancer patients was 2.5 to 4.0 folds 
higher than that in healthy volunteers. GM2AP is a glyco-
protein with molecular mass of 17.6 kDa in its deglycosyl-
ated form.7 It is an important cofactor for the degradation of 
GM2 ganglioside to GM3 by lysosomal β-hexminidase A.8,9 It 
is also associated with the changing level of ganglioside and 
tumor-associated gangliosides found in cancer progression. 
Tumor-associated gangliosides are a result of initial oncogenic 
transformation and play important roles in the induction of 
cancer invasion and metastasis.10,11 Tumor cells synthesize and 
shed gangliosides into their microenvironments, leading to ele-
vated levels of tumor-associated gangliosides in the serum.12 
Up to now, the clinical implications of measuring GM2AP in 
urine, serum, and tissue specimens in lung cancer patient have 
not been fully investigated. The objectives of this study were 
to measure the expression of GM2AP level in urine, serum, 
and tissue specimens of patients with lung cancer, and to cor-




Urine and serum samples from 133 patients with lung 
cancer, before receiving any anticancer treatment were con-
secutively collected at National Taiwan University Hospital, 
Taipei, Taiwan from January, 2012 to June, 2013. The study 
population included 60 (46%) male and 73 (54%) female 
patients, with a mean age of 62 (range, 30–81 years). 
 Forty-eight were smokers and 85 were never smokers. The 
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histology type included 109 adenocarcinoma, 4 SCLC, 11 
squamous cell carcinoma, and 9 other types of carcinoma. 
There were 18 patients in stage I, 6 in stage II, 25 in stage 
III, and 84 in stage IV. Sixty-six patients had tumors with 
activating mutations in epidermal growth factor receptor 
(EGFR), 58 patients had tumors with wild-type EGFR, and 
unknown EGFR mutation status in 9 patients. (Table 1). The 
control group was collected from health screen department, 
26 healthy volunteers donated urine samples with a mean age 
of 60 (range, 27–78 years) and 30 healthy volunteers donated 
serum samples with a mean age of 64 (range, 30–73 years).
Paraffin-embedded pathologic tissue specimens from 
143 NSCLC patients were obtained from the archives of 
the Department of Pathology, National Taiwan University 
Hospital, Taipei, Taiwan. The cases selected were based on a 
distinctive pathologic diagnosis of NSCLC for patients who 
underwent surgical resection for tumor with curative intent 
without preoperative chemotherapy or radiotherapy from 
January, 2002 to December, 2006. The clinicopathologic 
features such as age, gender, cancer stage, date of recurrence, 
and date of decease were collected retrospectively by medical 
chart record and cancer registry system. There were 79 (55%) 
male and 64 (45%) female patients with a mean age of 65.3 
(range, 33–82 years). There were 60 patients in stage I, 61 in 
stage II, 20 in stage III, and 2 in stage IV (Table 2). Tumor 
stage was defined according to the American Joint Committee 
on Caner/International Union against Cancer Tumor-node-
metastasis classification system.13 Lung tissues from unaf-
fected parts of the patients with lung cancer were used as 
controls. The study was approved by the institute research 
ethic committee of National Taiwan University Hospital 
(NTUH REC no. 201103074RC).
Western Blotting
Fifteen micrograms of protein eluted from urine and serum 
samples were applied in each lane onto 14% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis. The proteins were 





n Mean ± SD p Value n Mean ± SD p Value
Healthy volunteers
Age
  Median, 60 yrs (range, 27–78) 26 0.18 ± 0.19
  Median, 64 yrs (range, 30–73) 30 0.17 ± 0.07
Gender
  Male 15 0.23 ± 0.19 0.219 13 0.19 ± 0.08 0.408
  Female 11 0.11 ± 0.09 17 0.16 ± 0.07
Patients with lung cancer
Age
  Median, 62 yrs (range, 30–81) 133 1.46 ± 1.55 133 0.92 ± 0.74
Gender
  Male 60 1.65 ± 1.86 0.212 60 1.03 ± 0.91 0.119
  Female 73 1.31 ± 1.25 73 0.83 ± 0.56
Smoking status
  No 85 1.36 ± 1.54 0.337 85 0.88 ± 0.77 0.400
  Yes 48 1.64 ± 1.58 48 0.99 ± 0.69
EGFR mutation status
  Wild type 58 1.28 ± 1.39 0.462 58 0.75 ± 0.39 0.102
  Activating mutation 66 1.47 ± 1.40 66 0.91 ± 0.60
  Unknown 9 2.56 ± 2.93 9 2.11 ± 1.82
Histology
  Adenocarcinoma 109 1.97 ± 1.45 0.415 109 0.90 ± 0.63 0.475
  Small cell lung cancer 4 1.09 ± 0.85 4 0.78 ± 0.63
  Squamous cell carcinoma 11 0.57 ± 0.48 11 1.11 ± 0.21
  Other types of carcinoma 9 1.95 ± 3.09 9 1.26 ± 1.72
Pathologic stage
  I 18 2.31 ± 1.39 0.009 18 1.61 ± 0.93 <0.0001
  II 6 2.53 ± 3.65 6 1.47 ± 2.0
  III 25 1.57 ± 1.40 25 0.98 ± 0.52
  IV 84 1.17 ± 1.31 84 0.71 ± 0.43
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Bedford, MA) and blocked with 5% bovine serum albumin in 
phosphate buffered saline containing 0.05% Tween 20 (PBST) 
at 37°C overnight. The membrane was incubated with rabbit 
polyclonal antihuman GM2AP primary antibody (1:1000 dilu-
tion, Abcam, Cambridge, United Kingdom) at room temperature 
for 2 hours, followed by an antirabbit horseradish peroxidase-
conjugated secondary antibody (Abcam) at room temperature for 
1 hour. The blot was detected with an enhanced chemilumines-
cence Western blotting detection system (ECL Kit; PerkinElmer 
Waltham, MA) and exposed to Fujifilm LAS-4000 Luminescent 
Image Analyzer (FUJIFILM Corporation, Tokyo, Japan).
Enzyme-Linked Immunosorbent Assay Assay
The GM2AP level was assayed using commercially 
available sandwich enzyme-linked immunosorbent assay 
(ELISA) kits (Uscn Life Science Inc., Wuhan, P.R. China). 
The sensitivity limit of the GM2AP assay was 0.156 to 
10 ng/ml. The analyses were performed in duplicate according 
to the manufacturer’s instructions.
Immunohistochemical (IHC) Staining
The tissue slides were deparaffinized in xylene, rehy-
drated through graded alcohol, immersed in 3% hydrogen 
peroxide at 37°C for 10 minutes to block endogenous per-
oxidase activity. Subsequently, the slides were incubated with 
rabbit anti-GM2AP antibody (Abcam) at 4°C overnight. The 
slides were sequentially incubated with a secondary antibody 
(Abcam) at room temperature for 1 hour and stained with 3, 
3-diaminobenzidine. Finally, the sections were counterstained 
with hematoxylin. Using ImageScope software (Aperio 
Technologies, Vista, CA), morphometry was performed on 
entire tissue sections stained with antibodies against GM2AP. 
Immunohistochemical (IHC) detection was used to determine 
the GM2AP levels by adding the percentage score to the stain-
ing intensity score. The percentage of positively stained cells 
was scored as 0, 0%; score 1, 1 to 20%; and score 2, 20 to 
100%. Intensity was scored as 0, negative staining; 1, moder-
ate staining; and 2, strong staining. The composite IHC scor-
ing system was: IHC score = 0, for positive staining in 0% 
tumor cells; IHC score = 1, for moderate staining or strong 
staining in ≤20% tumor cells; IHC score = 2, for strong stain-
ing in more than 20% tumor cells.
Statistical Analyses
Statistical analysis was performed using the SPSS for 
Windows version 17.0 (SPSS Inc, Chicago, IL). Receiver-
operating characteristic (ROC) curves display the trade-off 
between sensitivity and specificity for biomarkers differenti-
ating between patients and healthy volunteers. The correlation 
between GM2AP expression and clinicopathologic features 
of patients with lung cancer was evaluated by the Chi-square 
test or Fisher’s exact test. Univariate and multivariate survival 
analyses were performed using the Cox proportional hazards 
regression model. Survival curves were obtained with the 
Kaplan-Meier method. Differences were considered statisti-
cally significant when p value was less than 0.05.
RESULTS
The Expression of GM2AP Level in Urine 
and Serum Specimens of Patients with 
Lung Cancer and Healthy Volunteers
First, urine and serum samples of the 40 lung cancer 
patients were examined by Western blotting, using those from 
healthy volunteers as controls. The result showed that the rep-
resentative blots of urinary GM2AP from patients with lung 
cancer and healthy volunteers (Supplementary Figure 1A, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A728). The representative blots of GM2AP in serum sam-
ples were shown in Supplementary Figure 1B (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A728). Levels of 
GM2AP in urine and serum samples were greatly increased in 
patients when compared with those from healthy volunteers. To 
quantify the GM2AP levels in urine and serum samples from 
patients with lung cancer and healthy volunteers, an ELISA 
assay was employed in this study. The mean urinary GM2AP 
level in all 133 lung cancer patients was 1.46 ± 1.55 ng/ml, 
and was 0.18 ± 0.19 ng/ml in healthy volunteers. There was 
an 8.11 ± 1.36 folds increase of GM2AP level in urine, and a 
5.41 ± 0.73 folds increase in the serum compared with those 
obtained from healthy volunteers. ROC curve analysis showed 
that the urinary GM2AP predicts the diagnosis of lung cancer 
with an AUC of 0.890 (95% confidence interval [CI], 0.83–
0.95) at a cutoff point of 0.234 ng/ml. This cutoff point pro-
vides 88.46% sensitivity and 85.71% specificity as shown in 
Figure 1A. A dot histogram plot demonstrates the distribution 
of GM2AP levels in urines of healthy volunteers (Figure 1B). 
The mean serum GM2AP level in patients with lung cancer 
was 0.92 ± 0.74 ng/ml, whereas the mean of GM2AP level 
in healthy volunteers was 0.17 ± 0.07 ng/ml. The ROC curve 
showed an AUC of 0.90 (95% CI, 0.85–0.95) at a cutoff point 
of 0.342 ng/ml, achieving 100% sensitivity and 82.71% speci-





p Value0 (n = 21) 1 (n = 92) 2 (n = 30)
Age
  Median (range) 64 (38–76) 64 (33–81) 68 (41–82) 0.425
Gender
  Male 11 52 16 0.916
  Female 10 40 14
Histology
  Adenocarcinoma 16 72 18 0.234
  Squamous cell 
carcinoma
4 15 7




  I 15 30 15 0.001
  II 3 48 10
  III 1 14 5
  IV 2 0 0
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plot was shown in Figure 1D. The results suggested a signifi-
cant increase of GM2AP levels in urine and serum of lung 
cancer patients (p < 0.0001), and a high accuracy for diag-
nosing lung cancer using established cutoff points. We fur-
ther compared GM2AP expression in serum of cancers other 
than lung origin, including colorectal cancer and liver cancer. 
We found that GM2AP expression in serum samples were 
highly increased only in patients with lung cancer (p < 0.05). 
The mean serum GM2AP level in patients with lung cancer, 
colorectal cancer, liver cancer, and healthy volunteers were 
0.92 ± 0.74, 0.17 ± 0.05, 0.17 ± 0.02, and 0.17 ± 0.07 ng/ml, 
respectively (Supplementary Table 1, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A729). The serum levels 
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to healthy volunteers (Supplementary Figure 2, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A728).
The Correlation Between the Expression 
of GM2AP in Urine and Serum of Lung 
Cancers and Clinicopathologic Features
We correlated the GM2AP levels in urine and serum 
with the clinicopathologic features of lung cancer patients. 
The urine level of GM2AP was similar in both genders: male 
(1.65 ± 1.86 ng/ml) and female (1.31 ± 1.25 ng/ml). There was 
no difference in the urinary GM2AP levels between the non-
smokers (1.36 ± 1.54 ng/ml) and smokers (1.64 ± 1.58 ng/ml). 
The levels of urinary GM2AP was also similar among those 
with activating EGFR mutation (1.47 ± 1.40 ng/ml), wild-type 
EGFR (1.28 ± 1.39 mg/ml), and unknown (2.56 ± 2.93 ng/ml). 
There was no difference in urinary GM2AP levels among dif-
ferent histology subtypes, and were 1.97 ± 1.45, 1.09 ± 0.85, 
0.57 ± 0.48, and 1.95 ± 3.09 ng/ml for adenocarcinoma, SCLC, 
squamous cell carcinoma, and other types of carcinoma, respec-
tively. Earlier stages had higher urinary GM2AP levels, which 
were 2.31 ± 1.39, 2.53 ± 3.65, 1.57 ± 1.40, and 1.17 ± 1.31 ng/ml 
for stages I, II, III, and IV, respectively (p = 0.009, Table 1).
The serum levels of GM2AP were also similar in both 
genders: male (1.03 ± 0.91 ng/ml) and female (0.83 ± 0.56 ng/
ml). There was no difference related to smoking status: non-
smokers (0.88 ± 0.77 ng/ml) versus smokers (0.99 ± 0.69 ng/ ml), 
and EGFR mutation status: activating EGFR mutations 
(0.91 ± 0.60 ng/ml), wild-type EGFR (0.75 ± 0.39 ng/ml) versus 
unknown (2.11 ± 1.82 ng/ml). There was no difference in serum 
GM2AP levels among histology subtypes, and were 0.90 ± 0.63, 
0.78 ± 0.63, 1.10 ± 0.21, and 1.26 ± 1.72 ng/ml for adenocarci-
noma, SCLC, squamous cell carcinoma, and other types of car-
cinoma, respectively. Earlier stages had higher serum GM2AP 
level: 1.61 ± 0.93, 1.47 ± 2.00, 0.98 ± 0.52, and 0.71 ± 0.43 ng/ml 
for stages I, II, III, and IV, respectively (p < 0.0001, Table 1).
In brief, no difference was shown in urinary or serum 
GM2AP levels when stratified by gender, smoking status, 
EGFR status, or histology subtypes. However, we demon-
strated a significant difference in urinary and serum GM2AP 
level among pathology stages (p = 0.009 for urine levels and 
p < 0.0001 for serum levels, respectively).
The Expression of GM2AP 
Level in NSCLC Tissues
The expression of GM2AP was detectable by IHC in 
lung tissue samples from 122 of 143 patients with NSCLC 
[90 of 106 invasive adenocarcinoma, 22 of 26 squamous 
cell carcinoma, and 10 of 11 adenocarcinoma in situ (previ-
ously named bronchioloalveolar carcinoma)], which makes 
a 83.9% positive rate of tissue expression of GM2AP in 
NSCLC and the majority were observed in the cytoplasm as 
brown granules via staining (Figure 2). The distribution of 
composite IHC score was 21 in score 0, 92 in score 1, and 
30 in score 2.
The Correlation Between the Expression 
of GM2AP in NSCLC Tissues and 
Clinicopathologic Feathers
There is no difference among different histology sub-
types in GM2AP expression. But there is a significant cor-
relation between GM2AP expression and pathology stages 
(p = 0.001). The positive rate of GM2AP was 75.0% (45 of 
60) in stage I, 95.1% (58 of 61) in stage II, and 95.0% (19 of 
20) in stage III, but 0% in stage IV (0 of 2). There were no 
statistical correlations between GM2AP expression and the 
remaining clinicopathologic features, such as age and gender 
(Table 2).
The Association Between Expression of 
GM2AP in NSCLC Tissues and Survival
The association between tissue GM2AP expression 
and the survival of 143 NSCLC patients was analyzed with 
Kaplan-Meier survival analysis. Patients with a high GM2AP 
expression (Score 2) were likely to have a significantly shorter 
overall survival (p = 0.045) (Figure 3A) and disease-free sur-
vival (p = 0.049) (Figure 3B). As GM2AP expression was 
significantly correlated with pathologic stage, we further 
determined the impact of GM2AP IHC score and pathology 
stage on the survival of NSCLC patients. The multivariate 
analysis of disease-free survival revealed that in addition to 
the stage [stage I/II vs. III/IV; hazard ratio (HR), 0.364 (95% 
CI, 0.216–0.612); p < 0.001], the IHC score [0/1 vs. 2; HR, 
0.563 (95% CI, 0.349–0.910); p = 0.024] was also an indepen-
dent predictor of disease recurrence (Table 3). Similar results 
were also shown in overall survival, in which the stage I/II 
versus III/IV [HR, 0.335 (95% CI, 0.163–0.689); p = 0.003] 
and the IHC score; 0/1 versus 2 [HR, 0.475 (95% CI, 0.250–
0.906); p = 0.024] was both independent predictors (Table 3).
DISCUSSION
Previously, Tantipaiboonwong et al5 first used 2-DE 
and matrix-assisted laser desorption ionization-time of flight 
mass spectrometry in search of urinary biomarkers of lung 
cancer, and reported six upregulated protein spots and three 
downregulated protein spots in patients with lung cancer com-
pared with what observed in the healthy volunteers. Among 
the upregulated spots, GM2AP was present at 2.5 to 4.0 folds 
higher than the level found in healthy volunteers. Those results 
were consistent with the recent findings reported in the study 
by Potprommanee et al.6 They used 2-DE and 2-DE Western 
blotting in the 2-DE region to confirm the expression of uri-
nary GM2AP level of individual patients with lung cancer. 
The urinary GM2AP level was found to increase in patient 
with lung cancer compared with that the healthy volunteers, 
suggesting that the urinary GM2AP level is potentially useful 
as a biomarker for lung cancer.
GM2AP is an essential cofactor for the degradation 
of GM2 ganglioside to GM3 by lysosomal hexminidase A. 
However, only one-third of the synthesized of GM2AP is 
secreted.14,15 Cells can recapture the GM2AP via a carbo-
hydrate-independent mechanism by various cells such as 
epidermal keratinocytes and fibroblast cells.15 A lack of the 
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functional GM2AP is a cause of the abnormal accumulation 
of GM2 ganglioside in tissues of patients with the AB variant 
of GM2 gangliosidosis disease.16 The inherited deficiency of 
GM2AP was also related to the changing level of ganglio-
side and tumor-associated gangliosides involving in cancer 
progression. Tumor-associated gangliosides are a result of 
initial oncogenic transformation and play a role in the induc-
tion of invasion and metastasis.10,11 Moreover, gangliosides 
are known to exhibit regulatory roles in cell growth, adhe-
sion, cell–cell interactions, and signal transduction.17 Tumor 
cells synthesized and shed gangliosides into their microen-
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gangliosides in the serum.18,19 As previously reported, the 
expression of urinary GM2AP level was higher in patients 
with lung cancer compared with that of the healthy volun-
teers. Urine is produced by the kidneys and allows the human 
body to eliminate waste substances through a filtration of the 
blood.20 We also hypothesized that the increased levels of uri-
nary GM2AP may come from  distant organs via plasma that 
obtained through glomerular filtration. However, no study has 
been carried out to investigate the levels of GM2AP and its 
clinical roles in large number of urine, or biological samples 
besides urine from patients with lung cancer.
In this study, we have further confirmed the expres-
sion of GM2AP in a large group of patients with lung can-
cer using urine and serum specimens. We found that the 
levels of urinary or serum GM2AP was much higher in 
patients with lung cancer than in healthy volunteers. The 
areas under ROC curve demonstrated that both urinary and 
serum GM2AP can be a potential diagnostic markers for 
lung cancer. The urinary GM2AP possessed an AUC value 
at 0.89 (95% CI, 0.83– 0.95) with sensitivity of 88.46% and 
a specificity of 85.71%, and serum GM2AP showed an AUC 
value at 0.90 (95% CI, 0.85– 0.95) with sensitivity of 100% 
and a specificity of 82.71%, respectively. To confirm the 
specificity of GM2AP in diagnosing lung cancer, the serum 
samples from patients with colorectal cancer and liver can-
cer were examined. Our results supported that GM2AP was 
a more specific marker for lung cancer, because the GM2AP 
level in colorectal cancer or liver cancer was the same as in 
healthy volunteers.
Despite tremendous works endeavored in seeking for 
specific cancer markers, very few have become clinically 
applicable. Prostate-specific antigen in prostate cancer21 
and CA-125 in gynecological oncology are examples.22,23 
Recently, researchers have suggested many serum-detect-
able biomarkers for cancers24–28 but few have been success-
fully adapted into clinical application, especially for early 
detection. In this study, we found that the expression of 
GM2AP in both urine and serum are significantly corre-
lated with pathology stage. In earlier stages of lung cancer, 
the levels of GM2AP were higher. Using IHC, we demon-
strated that GM2AP was expressed essentially by tumor 
cells. None of the surrounding nontumor tissue expressed 
GM2AP. Except pathology stages, there was no correlation 
between the GM2AP expression and histology type, age, 
and gender. The rate of GM2AP expression or IHC score 2 
in stages I, II, and III was similar, but much lower in stage 
IV. Our results suggest that urine and serum GM2AP levels 
can be potential markers for assisting lung cancer diagnosis, 
especially for early lung cancer. The aberrant expression of 
GM2AP is related to tumor-associated gangliosides involv-
ing in cancer progression and plays a role in the induction 
of invasion and metastasis.11 Antitumor immune response 
was suppressed by gangliosides synthesized by tumor cells 
and shed into their microenvironment.29–34 Many studies 
have shown that  tumor-derived gangliosides inhibit the cel-
lular immune response in vitro, such as natural killer cell 
cytotoxicity.35–37 Recent study showed that GM2AP impairs 
insulin  signaling.38 It is possible that GM2AP may inhibit 
insulin signaling to reduce uptake glucose in normal cell, 
therefore, cancer cell will have more glucose to support cell 
growth. However, GM2AP can hydrolyze platelet-activating 
 factor and inhibit platelet-activating factor-initiation inflam-
mation response,39 hence, GM2AP may help cancer cell to 
escape from antitumor response by inhibiting inflamma-
tion. Because GM2AP expression at stages III and IV was 
lower than stages I and II, the anti-inflammatory property 
of GM2AP may play an important role in earlier stage of 
cancer through reducing immune response that recognizes 
or destroys tumor cell. However, this hypothesis needs to 
be confirmed.
Besides being a diagnostic marker, GM2AP can also be 
a prognostic marker. The higher expression of GM2AP (IHC 
score 2) predicted shorter overall survival and  disease-free sur-
vival. The results of multivariate analysis suggested GM2AP 
score is an independent prognostic factor besides pathology 
stage. As GM2AP is related to tumor invasion and metastasis, 
a higher expression of GM2AP in early stages of lung cancer 
may imply early metastatic disease. This finding supported 
that GM2AP may be a pivotal modulator involved in lung 
cancer development according to our experimental data indi-
cating no relationships between the GM2AP expression level 
and other types of cancers.
In summary, the level of GM2AP in urines and sera 
can be useful for assisting the diagnosis of lung cancer. The 
expression of GM2AP in lung cancer tissues could be a good 
prognostic factor for NSCLC, especially in early stage, in 
predicting both overall survival and disease-free survival, this 
protein has a great potential to serve as both diagnostic and 
prognostic marker for lung cancer, but its mechanism requires 
further detailed investigations.
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Variable Hazard ratio (95% CI) p Value
Disease-free survival
  Stage I + II vs. stage III + IV 0.364 (0.216–0.612) <0.001
  IHC score 0 + 1 vs. 2 0.563 (0.349–0.910 0.019
Overall survival
  Stage I + II vs. stage III + IV 0.335 (0.163–0.689) 0.003
  IHC score 0 + 1 vs. 2 0.475 (0.250–0.906) 0.024
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